Literature DB >> 14523943

Targeting dendritic cells for priming cellular immune responses.

Péter Gogolák1, Bence Réthi, György Hajas, Eva Rajnavölgyi.   

Abstract

The cardinal role of dendritic cells (DC) in priming adaptive immunity and in orchestrating immune responses against all classes of pathogens and also against tumors is well established. Their unique potential both to maintain self-tolerance and to initiate protective immune responses against foreign and/or dangerous structures is based on the functional diversity and flexibility of these cells. Tissue DC lining antigenic portals such as mucosal surfaces and the skin are specialized to take up a wide array of compounds including proteins, lipids, carbohydrates, glycoproteins, glycolipids and oligonucleotides, particles carrying such structures and apoptotic or necrotic cells. This process is facilitated by specialized receptors with high endocytic capacity, which provides potential targets for delivering designed molecules. The best route for targeting B- and/or T cell epitopes, however, is still the subject of intense investigation. Immature DC, which reside in various tissues, can be activated by pathogens, stress and inflammation or modified metabolic products, which induce mobilization of cells to draining lymph nodes where they act as highly potent professional antigen presenting cells. This is brought about by the ability to present their accumulated intracellular content for both CD4+ helper (Th) and CD8+ cytotoxic/cytolytic T lymphocytes (Tc/CTL). Engulfed proteins are processed intracellularly and their peptide fragments are transported to the cell surface in the context of major histocompatibility complex encoded class I and II molecules for presentation to Th cells and CTLs, respectively. The T cell priming capacity of DC, however, depends not only on antigen presentation but also on other features of DC. Human monocyte-derived DC provide an excellent tool to study the internalizing, antigen-presenting and T cell-activating functions of DC at their immature and activated differentiation states. These biological activities of DC, however, are highly dependent on their migratory potential from the peripheral non-lymphoid tissues to the lymph nodes, on the expression of adhesion molecules, which support the interaction of DC with T lymphocytes, and the cytokines secreted by DC, which polarize immune responses to Th1-mediated cellular or Th2-mediated antibody responses. These results altogether demonstrate that monocyte-derived DC are useful candidates for in vitro or in vivo targeting of antigens to induce efficient adaptive immune responses against pathogens and also against tumors. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14523943     DOI: 10.1002/jmr.650

Source DB:  PubMed          Journal:  J Mol Recognit        ISSN: 0952-3499            Impact factor:   2.137


  12 in total

1.  Inflammatory events in a vascular remodeling model induced by surgical injury to the rat carotid artery.

Authors:  Barbara Rinaldi; Paolo Romagnoli; Stefano Bacci; Rosa Carnuccio; Maria Chiara Maiuri; Maria Donniacuo; Annalisa Capuano; Francesco Rossi; Amelia Filippelli
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

2.  The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions.

Authors:  Fiona A Harding; Marcia M Stickler; Jennifer Razo; Robert B DuBridge
Journal:  MAbs       Date:  2010-05-01       Impact factor: 5.857

Review 3.  Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review.

Authors:  Asfar S Azmi; Bin Bao; Fazlul H Sarkar
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

Review 4.  Vaccine adjuvants: current challenges and future approaches.

Authors:  Jennifer H Wilson-Welder; Maria P Torres; Matt J Kipper; Surya K Mallapragada; Michael J Wannemuehler; Balaji Narasimhan
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

5.  Microparticle surface modifications targeting dendritic cells for non-activating applications.

Authors:  Jamal S Lewis; Toral D Zaveri; Charles P Crooks; Benjamin G Keselowsky
Journal:  Biomaterials       Date:  2012-07-12       Impact factor: 12.479

6.  Processing and presentation of exogenous HLA class I peptides by dendritic cells from human immunodeficiency virus type 1-infected persons.

Authors:  Xiao-Li Huang; Zheng Fan; Bonnie A Colleton; Rico Buchli; Hongyi Li; William H Hildebrand; Charles R Rinaldo
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

Review 7.  Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking.

Authors:  João Conniot; Joana M Silva; Joana G Fernandes; Liana C Silva; Rogério Gaspar; Steve Brocchini; Helena F Florindo; Teresa S Barata
Journal:  Front Chem       Date:  2014-11-26       Impact factor: 5.221

8.  Molecular and Cellular Mechanisms of Antitumor Immune Response Activation by Dendritic Cells.

Authors:  O V Markov; N L Mironova; V V Vlasov; M A Zenkova
Journal:  Acta Naturae       Date:  2016 Jul-Sep       Impact factor: 1.845

Review 9.  Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications.

Authors:  Anshu Kuriakose; Narendra Chirmule; Pradip Nair
Journal:  J Immunol Res       Date:  2016-06-29       Impact factor: 4.818

10.  Enhanced immune response induced by P5 HER2/neu-derived peptide-pulsed dendritic cells as a preventive cancer vaccine.

Authors:  Zahra Gholizadeh; Jalil Tavakkol-Afshari; Amin Reza Nikpoor; Seyed Amir Jalali; Mahmoud Reza Jaafari
Journal:  J Cell Mol Med       Date:  2017-09-25       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.